Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Ibezapolstat & Clostridioides difficile infection (CDI) (initial), no FDA or EMA approval exists yet for ibezapolstat in CDI (initial or recurrent); it is still in the pre‑registration/Phase III‑readiness stage (1).
The randomized clinical phase II treatment trial NCT04247542 - Ibezapolstat vs Vancomycin & Clostridioides difficile infection (CDI) (initial) revealed that Ibezapolstat is an antibiotic with a selective spectrum targeting Gram-positive bacteria. It shows promise in treating initial [Clostridio…